ASP Isotopes (ASPI) Q3 2026: The Numbers Behind the 10-Q
Flat revenue, a $9.6M stock-comp quarter, and a much lighter balance sheet after the July note exchange. Full earnings model and analysis inside.
ASP Isotopes filed its Q3 2026 10-Q on November 16. We rebuilt the quarter line by line against Q2 2026 and Q3 2025, broke out all three segments, and built a five-quarter cash runway model. As always, this is research only. No ratings, no price targets, no recommendations.
The quarter at a glance
Revenue: $5.1M, flat on Q2 ($5.1M) and 4.0x Q3 2025 ($1.3M). Product revenue rose 13% QoQ; Q2’s $0.6M of collaboration revenue did not repeat.
Gross profit: $0.8M, down from $1.5M. Gross margin fell to 15.5% from 28.9%.
Loss from operations: $40.5M, 18% wider than Q2’s $34.2M.
Stock-based compensation: $9.6M, up from $4.5M in Q2. Operating expenses excluding SBC rose 2%.
Net loss: $30.9M, narrower than Q2’s $34.0M, but that includes an $11.25M non-cash gain on the July note exchange. Excluding the gain, the net loss was $42.1M.
Balance sheet: convertible notes at fair value fell to $85.9M from $203.4M after $109.2M of principal was exchanged for about 23.2M shares. Total liabilities fell $118.4M QoQ.
Cash: $201.7M unrestricted at September 30, plus $20.9M restricted. No short-term investments remain. Q3 operating cash use plus capex was $28.7M.
Debt: $53.0M total, $47.7M of it current. The DFC facility at Renergen is in default and the SBSA loan is in breach; both, along with the IDC loan, are classified current.
By segment (Q3 2026)
Specialist isotopes: revenue $4.3M (+10% QoQ), gross margin 38.2% (Q2 44.5%, Q1 50.0%), segment loss $18.6M.
Nuclear fuels: no revenue; segment loss $11.5M.
Helium & LNG: revenue $0.9M (+33% QoQ), gross margin -96%, segment loss $10.4M (Q2 $5.8M).
What’s in the full package (paid subscribers)
The live Excel model (11 tabs, every figure sourced to the 10-Qs):
Quarterly P&L for Q3 2025 and Q1 through Q3 2026, with QoQ, YoY and nine-month totals
Segment detail for all three segments: revenue, cost of sales, personnel, professional fees, other expenses and operating loss
Balance sheet across four quarter-ends, capital structure, the debt facility table and the note exchange
Quarterly cash flow plus the nine-month cash flow detail
A forecast through Q4 2027 under Low, Base and High scenarios, with yellow lever cells you can change: segment growth, gross margins, cash opex growth, cash conversion, capex, net interest and debt repayment
A checks tab that ties the P&L subtotals, segment totals and nine-month totals back to the reported figures
The 6-page PDF analysis:
Key points and a plain read of the quarter
Full results table against Q2 2026 and Q3 2025
Segment charts and commentary
Balance sheet, debt and share count changes
Cash flow and the nine-month cash bridge
Scenario runway: when unrestricted cash falls below a $50M buffer in each case
Dated items to track: the ENDRA/Renergen merger (4K Resources), first Si-28 and Yb-176 sales, the QLE listing plan and Virginia Gas Phase 2

